GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » Current Deferred Revenue

Aptamer Group (LSE:APTA) Current Deferred Revenue : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Aptamer Group's current deferred revenue for the quarter that ended in Dec. 2023 was £0.00 Mil.

Aptamer Group Current Deferred Revenue Historical Data

The historical data trend for Aptamer Group's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group Current Deferred Revenue Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23
Current Deferred Revenue
- - - -

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

Aptamer Group Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Aptamer Group's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptamer Group (LSE:APTA) Business Description

Traded in Other Exchanges
N/A
Address
Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group (LSE:APTA) Headlines

No Headlines